AustralieFrV1, PascalFrancis, Corpus, bibRecord, 000795

Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex

Identifieur interne : 000795 ( PascalFrancis/Corpus ); précédent : 000794; suivant : 000796

Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex

Auteurs : Frank Ruschitzka ; William T. Abraham ; Jagmeet P. Singh ; Jeroen J. Bax ; Jeffrey S. Borer ; Josep Brugada ; Kenneth Dickstein ; Ian Ford ; John Iii Gorcsan ; Daniel Gras ; Henry Krum ; Peter Sogaard ; Johannes Holzmeister

Source :

The New England journal of medicine [ 0028-4793 ] ; 2013.

RBID : Pascal:13-0314576

Descripteurs français

Pascal (Inist)
- Insuffisance cardiaque, Traitement instrumental, Médecine, Resynchronisation cardiaque.

English descriptors

KwdEn :
- Cardiac resynchronization, Heart failure, Instrumentation therapy, Medicine.

Abstract

BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. METHODS We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. RESULTS On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). CONCLUSIONS In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-4793`
A02	`01`			`@0 NEJMAG`
A03		`1`		`@0 N. Engl. j. med.`
A05				`@2 369`
A06				`@2 15`
A08	`01`	`1`	`ENG`	`@1 Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex`
A11	`01`	`1`		`@1 RUSCHITZKA (Frank)`
A11	`02`	`1`		`@1 ABRAHAM (William T.)`
A11	`03`	`1`		`@1 SINGH (Jagmeet P.)`
A11	`04`	`1`		`@1 BAX (Jeroen J.)`
A11	`05`	`1`		`@1 BORER (Jeffrey S.)`
A11	`06`	`1`		`@1 BRUGADA (Josep)`
A11	`07`	`1`		`@1 DICKSTEIN (Kenneth)`
A11	`08`	`1`		`@1 FORD (Ian)`
A11	`09`	`1`		`@1 GORCSAN (John III)`
A11	`10`	`1`		`@1 GRAS (Daniel)`
A11	`11`	`1`		`@1 KRUM (Henry)`
A11	`12`	`1`		`@1 SOGAARD (Peter)`
A11	`13`	`1`		`@1 HOLZMEISTER (Johannes)`
A14	`01`			`@1 Clinic for Cardiology, University Hospital Zurich @2 Zurich @3 CHE @Z 1 aut. @Z 13 aut.`
A14	`02`			`@1 Division of Cardiovascular Medicine, Ohio State University Medical Center, Davis Heart and Lung Research Institute @2 Columbus @3 USA @Z 2 aut.`
A14	`03`			`@1 Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School @2 Boston @3 USA @Z 3 aut.`
A14	`04`			`@1 Department of Cardiology, Leiden University Medical Center @2 Leiden @3 NLD @Z 4 aut.`
A14	`05`			`@1 Division of Cardiovascular Medicine and Howard Gilman and Ron and Jean Schiavone Institutes, State University of New York Downstate College of Medicine @2 New York @3 USA @Z 5 aut.`
A14	`06`			`@1 Cardiology Department, Thorax Institute, Hospital Clinic, University of Barcelona @2 Barcelona @3 ESP @Z 6 aut.`
A14	`07`			`@1 University of Bergen, Stavanger University Hospital @2 Stavanger @3 NOR @Z 7 aut.`
A14	`08`			`@1 Robertson Centre for Biostatistics, University of Glasgow @2 Glasgow @3 GBR @Z 8 aut.`
A14	`09`			`@1 University of Pittsburgh @2 Pittsburgh @3 USA @Z 9 aut.`
A14	`10`			`@1 Nouvelles Cliniques Nantaises @2 Nantes @3 FRA @Z 10 aut.`
A14	`11`			`@1 Monash Centre of Cardiovascular Research and Education in Therapeutics @2 Melbourne, VIC @3 AUS @Z 11 aut.`
A14	`12`			`@1 Aalborg University @2 Aalborg @3 DNK @Z 12 aut.`
A17	`01`	`1`		`@1 EchoCRT Study Group @3 INC`
A20				`@1 1395-1405`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6013 @5 354000505862220050`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 32 ref.`
A47	`01`	`1`		`@0 13-0314576`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The New England journal of medicine`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. METHODS We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. RESULTS On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). CONCLUSIONS In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B12A01`
C03	`01`	`X`	`FRE`	`@0 Insuffisance cardiaque @5 01`
C03	`01`	`X`	`ENG`	`@0 Heart failure @5 01`
C03	`01`	`X`	`SPA`	`@0 Insuficiencia cardíaca @5 01`
C03	`02`	`X`	`FRE`	`@0 Traitement instrumental @5 04`
C03	`02`	`X`	`ENG`	`@0 Instrumentation therapy @5 04`
C03	`02`	`X`	`SPA`	`@0 Tratamiento instrumental @5 04`
C03	`03`	`X`	`FRE`	`@0 Médecine @5 07`
C03	`03`	`X`	`ENG`	`@0 Medicine @5 07`
C03	`03`	`X`	`SPA`	`@0 Medicina @5 07`
C03	`04`	`X`	`FRE`	`@0 Resynchronisation cardiaque @4 CD @5 96`
C03	`04`	`X`	`ENG`	`@0 Cardiac resynchronization @4 CD @5 96`
C07	`01`	`X`	`FRE`	`@0 Stimulation instrumentale @5 37`
C07	`01`	`X`	`ENG`	`@0 Instrumental stimulation @5 37`
C07	`01`	`X`	`SPA`	`@0 Estimulación instrumental @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 38`
C07	`02`	`X`	`ENG`	`@0 Cardiovascular disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Cardiopathie @5 39`
C07	`03`	`X`	`ENG`	`@0 Heart disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Cardiopatía @5 39`
N21				`@1 294`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 13-0314576 INIST
ET :	Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex
AU :	RUSCHITZKA (Frank); ABRAHAM (William T.); SINGH (Jagmeet P.); BAX (Jeroen J.); BORER (Jeffrey S.); BRUGADA (Josep); DICKSTEIN (Kenneth); FORD (Ian); GORCSAN (John III); GRAS (Daniel); KRUM (Henry); SOGAARD (Peter); HOLZMEISTER (Johannes)
AF :	Clinic for Cardiology, University Hospital Zurich/Zurich/Suisse (1 aut., 13 aut.); Division of Cardiovascular Medicine, Ohio State University Medical Center, Davis Heart and Lung Research Institute/Columbus/Etats-Unis (2 aut.); Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School/Boston/Etats-Unis (3 aut.); Department of Cardiology, Leiden University Medical Center/Leiden/Pays-Bas (4 aut.); Division of Cardiovascular Medicine and Howard Gilman and Ron and Jean Schiavone Institutes, State University of New York Downstate College of Medicine/New York/Etats-Unis (5 aut.); Cardiology Department, Thorax Institute, Hospital Clinic, University of Barcelona/Barcelona/Espagne (6 aut.); University of Bergen, Stavanger University Hospital/Stavanger/Norvège (7 aut.); Robertson Centre for Biostatistics, University of Glasgow/Glasgow/Royaume-Uni (8 aut.); University of Pittsburgh/Pittsburgh/Etats-Unis (9 aut.); Nouvelles Cliniques Nantaises/Nantes/France (10 aut.); Monash Centre of Cardiovascular Research and Education in Therapeutics/Melbourne, VIC/Australie (11 aut.); Aalborg University/Aalborg/Danemark (12 aut.)
DT :	Publication en série; Niveau analytique
SO :	The New England journal of medicine; ISSN 0028-4793; Coden NEJMAG; Etats-Unis; Da. 2013; Vol. 369; No. 15; Pp. 1395-1405; Bibl. 32 ref.
LA :	Anglais
EA :	BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. METHODS We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. RESULTS On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). CONCLUSIONS In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.
CC :	002B01; 002B12A01
FD :	Insuffisance cardiaque; Traitement instrumental; Médecine; Resynchronisation cardiaque
FG :	Stimulation instrumentale; Pathologie de l'appareil circulatoire; Cardiopathie
ED :	Heart failure; Instrumentation therapy; Medicine; Cardiac resynchronization
EG :	Instrumental stimulation; Cardiovascular disease; Heart disease
SD :	Insuficiencia cardíaca; Tratamiento instrumental; Medicina
LO :	INIST-6013.354000505862220050
ID :	13-0314576

Links to Exploration step

Pascal:13-0314576

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex</title>
<author><name sortKey="Ruschitzka, Frank" sort="Ruschitzka, Frank" uniqKey="Ruschitzka F" first="Frank" last="Ruschitzka">Frank Ruschitzka</name>
<affiliation><inist:fA14 i1="01"><s1>Clinic for Cardiology, University Hospital Zurich</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Abraham, William T" sort="Abraham, William T" uniqKey="Abraham W" first="William T." last="Abraham">William T. Abraham</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Cardiovascular Medicine, Ohio State University Medical Center, Davis Heart and Lung Research Institute</s1>
<s2>Columbus</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Singh, Jagmeet P" sort="Singh, Jagmeet P" uniqKey="Singh J" first="Jagmeet P." last="Singh">Jagmeet P. Singh</name>
<affiliation><inist:fA14 i1="03"><s1>Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bax, Jeroen J" sort="Bax, Jeroen J" uniqKey="Bax J" first="Jeroen J." last="Bax">Jeroen J. Bax</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Cardiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Borer, Jeffrey S" sort="Borer, Jeffrey S" uniqKey="Borer J" first="Jeffrey S." last="Borer">Jeffrey S. Borer</name>
<affiliation><inist:fA14 i1="05"><s1>Division of Cardiovascular Medicine and Howard Gilman and Ron and Jean Schiavone Institutes, State University of New York Downstate College of Medicine</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brugada, Josep" sort="Brugada, Josep" uniqKey="Brugada J" first="Josep" last="Brugada">Josep Brugada</name>
<affiliation><inist:fA14 i1="06"><s1>Cardiology Department, Thorax Institute, Hospital Clinic, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dickstein, Kenneth" sort="Dickstein, Kenneth" uniqKey="Dickstein K" first="Kenneth" last="Dickstein">Kenneth Dickstein</name>
<affiliation><inist:fA14 i1="07"><s1>University of Bergen, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name>
<affiliation><inist:fA14 i1="08"><s1>Robertson Centre for Biostatistics, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gorcsan, John Iii" sort="Gorcsan, John Iii" uniqKey="Gorcsan J" first="John Iii" last="Gorcsan">John Iii Gorcsan</name>
<affiliation><inist:fA14 i1="09"><s1>University of Pittsburgh</s1>
<s2>Pittsburgh</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gras, Daniel" sort="Gras, Daniel" uniqKey="Gras D" first="Daniel" last="Gras">Daniel Gras</name>
<affiliation><inist:fA14 i1="10"><s1>Nouvelles Cliniques Nantaises</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation><inist:fA14 i1="11"><s1>Monash Centre of Cardiovascular Research and Education in Therapeutics</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sogaard, Peter" sort="Sogaard, Peter" uniqKey="Sogaard P" first="Peter" last="Sogaard">Peter Sogaard</name>
<affiliation><inist:fA14 i1="12"><s1>Aalborg University</s1>
<s2>Aalborg</s2>
<s3>DNK</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holzmeister, Johannes" sort="Holzmeister, Johannes" uniqKey="Holzmeister J" first="Johannes" last="Holzmeister">Johannes Holzmeister</name>
<affiliation><inist:fA14 i1="01"><s1>Clinic for Cardiology, University Hospital Zurich</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0314576</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0314576 INIST</idno>
<idno type="RBID">Pascal:13-0314576</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000795</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex</title>
<author><name sortKey="Ruschitzka, Frank" sort="Ruschitzka, Frank" uniqKey="Ruschitzka F" first="Frank" last="Ruschitzka">Frank Ruschitzka</name>
<affiliation><inist:fA14 i1="01"><s1>Clinic for Cardiology, University Hospital Zurich</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Abraham, William T" sort="Abraham, William T" uniqKey="Abraham W" first="William T." last="Abraham">William T. Abraham</name>
<affiliation><inist:fA14 i1="02"><s1>Division of Cardiovascular Medicine, Ohio State University Medical Center, Davis Heart and Lung Research Institute</s1>
<s2>Columbus</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Singh, Jagmeet P" sort="Singh, Jagmeet P" uniqKey="Singh J" first="Jagmeet P." last="Singh">Jagmeet P. Singh</name>
<affiliation><inist:fA14 i1="03"><s1>Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bax, Jeroen J" sort="Bax, Jeroen J" uniqKey="Bax J" first="Jeroen J." last="Bax">Jeroen J. Bax</name>
<affiliation><inist:fA14 i1="04"><s1>Department of Cardiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Borer, Jeffrey S" sort="Borer, Jeffrey S" uniqKey="Borer J" first="Jeffrey S." last="Borer">Jeffrey S. Borer</name>
<affiliation><inist:fA14 i1="05"><s1>Division of Cardiovascular Medicine and Howard Gilman and Ron and Jean Schiavone Institutes, State University of New York Downstate College of Medicine</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brugada, Josep" sort="Brugada, Josep" uniqKey="Brugada J" first="Josep" last="Brugada">Josep Brugada</name>
<affiliation><inist:fA14 i1="06"><s1>Cardiology Department, Thorax Institute, Hospital Clinic, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dickstein, Kenneth" sort="Dickstein, Kenneth" uniqKey="Dickstein K" first="Kenneth" last="Dickstein">Kenneth Dickstein</name>
<affiliation><inist:fA14 i1="07"><s1>University of Bergen, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ford, Ian" sort="Ford, Ian" uniqKey="Ford I" first="Ian" last="Ford">Ian Ford</name>
<affiliation><inist:fA14 i1="08"><s1>Robertson Centre for Biostatistics, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gorcsan, John Iii" sort="Gorcsan, John Iii" uniqKey="Gorcsan J" first="John Iii" last="Gorcsan">John Iii Gorcsan</name>
<affiliation><inist:fA14 i1="09"><s1>University of Pittsburgh</s1>
<s2>Pittsburgh</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gras, Daniel" sort="Gras, Daniel" uniqKey="Gras D" first="Daniel" last="Gras">Daniel Gras</name>
<affiliation><inist:fA14 i1="10"><s1>Nouvelles Cliniques Nantaises</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krum, Henry" sort="Krum, Henry" uniqKey="Krum H" first="Henry" last="Krum">Henry Krum</name>
<affiliation><inist:fA14 i1="11"><s1>Monash Centre of Cardiovascular Research and Education in Therapeutics</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sogaard, Peter" sort="Sogaard, Peter" uniqKey="Sogaard P" first="Peter" last="Sogaard">Peter Sogaard</name>
<affiliation><inist:fA14 i1="12"><s1>Aalborg University</s1>
<s2>Aalborg</s2>
<s3>DNK</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Holzmeister, Johannes" sort="Holzmeister, Johannes" uniqKey="Holzmeister J" first="Johannes" last="Holzmeister">Johannes Holzmeister</name>
<affiliation><inist:fA14 i1="01"><s1>Clinic for Cardiology, University Hospital Zurich</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The New England journal of medicine</title>
<title level="j" type="abbreviated">N. Engl. j. med.</title>
<idno type="ISSN">0028-4793</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cardiac resynchronization</term>
<term>Heart failure</term>
<term>Instrumentation therapy</term>
<term>Medicine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Insuffisance cardiaque</term>
<term>Traitement instrumental</term>
<term>Médecine</term>
<term>Resynchronisation cardiaque</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. METHODS We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. RESULTS On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). CONCLUSIONS In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-4793</s0>
</fA01>
<fA02 i1="01"><s0>NEJMAG</s0>
</fA02>
<fA03 i2="1"><s0>N. Engl. j. med.</s0>
</fA03>
<fA05><s2>369</s2>
</fA05>
<fA06><s2>15</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RUSCHITZKA (Frank)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ABRAHAM (William T.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SINGH (Jagmeet P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BAX (Jeroen J.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BORER (Jeffrey S.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BRUGADA (Josep)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DICKSTEIN (Kenneth)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>FORD (Ian)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>GORCSAN (John III)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GRAS (Daniel)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>KRUM (Henry)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SOGAARD (Peter)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>HOLZMEISTER (Johannes)</s1>
</fA11>
<fA14 i1="01"><s1>Clinic for Cardiology, University Hospital Zurich</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Division of Cardiovascular Medicine, Ohio State University Medical Center, Davis Heart and Lung Research Institute</s1>
<s2>Columbus</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School</s1>
<s2>Boston</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Cardiology, Leiden University Medical Center</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Division of Cardiovascular Medicine and Howard Gilman and Ron and Jean Schiavone Institutes, State University of New York Downstate College of Medicine</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Cardiology Department, Thorax Institute, Hospital Clinic, University of Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>University of Bergen, Stavanger University Hospital</s1>
<s2>Stavanger</s2>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Robertson Centre for Biostatistics, University of Glasgow</s1>
<s2>Glasgow</s2>
<s3>GBR</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>University of Pittsburgh</s1>
<s2>Pittsburgh</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Nouvelles Cliniques Nantaises</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Monash Centre of Cardiovascular Research and Education in Therapeutics</s1>
<s2>Melbourne, VIC</s2>
<s3>AUS</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Aalborg University</s1>
<s2>Aalborg</s2>
<s3>DNK</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>EchoCRT Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>1395-1405</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6013</s2>
<s5>354000505862220050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0314576</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The New England journal of medicine</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. METHODS We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. RESULTS On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). CONCLUSIONS In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B12A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Insuffisance cardiaque</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Heart failure</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Insuficiencia cardíaca</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement instrumental</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Instrumentation therapy</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento instrumental</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Médecine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Medicine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Medicina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Resynchronisation cardiaque</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cardiac resynchronization</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Stimulation instrumentale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Instrumental stimulation</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Estimulación instrumental</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Cardiopathie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Heart disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Cardiopatía</s0>
<s5>39</s5>
</fC07>
<fN21><s1>294</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 13-0314576 INIST</NO>
<ET>Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex</ET>
<AU>RUSCHITZKA (Frank); ABRAHAM (William T.); SINGH (Jagmeet P.); BAX (Jeroen J.); BORER (Jeffrey S.); BRUGADA (Josep); DICKSTEIN (Kenneth); FORD (Ian); GORCSAN (John III); GRAS (Daniel); KRUM (Henry); SOGAARD (Peter); HOLZMEISTER (Johannes)</AU>
<AF>Clinic for Cardiology, University Hospital Zurich/Zurich/Suisse (1 aut., 13 aut.); Division of Cardiovascular Medicine, Ohio State University Medical Center, Davis Heart and Lung Research Institute/Columbus/Etats-Unis (2 aut.); Cardiac Arrhythmia Service, Massachusetts General Hospital, Harvard Medical School/Boston/Etats-Unis (3 aut.); Department of Cardiology, Leiden University Medical Center/Leiden/Pays-Bas (4 aut.); Division of Cardiovascular Medicine and Howard Gilman and Ron and Jean Schiavone Institutes, State University of New York Downstate College of Medicine/New York/Etats-Unis (5 aut.); Cardiology Department, Thorax Institute, Hospital Clinic, University of Barcelona/Barcelona/Espagne (6 aut.); University of Bergen, Stavanger University Hospital/Stavanger/Norvège (7 aut.); Robertson Centre for Biostatistics, University of Glasgow/Glasgow/Royaume-Uni (8 aut.); University of Pittsburgh/Pittsburgh/Etats-Unis (9 aut.); Nouvelles Cliniques Nantaises/Nantes/France (10 aut.); Monash Centre of Cardiovascular Research and Education in Therapeutics/Melbourne, VIC/Australie (11 aut.); Aalborg University/Aalborg/Danemark (12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The New England journal of medicine; ISSN 0028-4793; Coden NEJMAG; Etats-Unis; Da. 2013; Vol. 369; No. 15; Pp. 1395-1405; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>BACKGROUND Cardiac-resynchronization therapy (CRT) reduces morbidity and mortality in chronic systolic heart failure with a wide QRS complex. Mechanical dyssynchrony also occurs in patients with a narrow QRS complex, which suggests the potential usefulness of CRT in such patients. METHODS We conducted a randomized trial involving 115 centers to evaluate the effect of CRT in patients with New York Heart Association class III or IV heart failure, a left ventricular ejection fraction of 35% or less, a QRS duration of less than 130 msec, and echocardiographic evidence of left ventricular dyssynchrony. All patients underwent device implantation and were randomly assigned to have CRT capability turned on or off. The primary efficacy outcome was the composite of death from any cause or first hospitalization for worsening heart failure. RESULTS On March 13, 2013, the study was stopped for futility on the recommendation of the data and safety monitoring board. At study closure, the 809 patients who had undergone randomization had been followed for a mean of 19.4 months. The primary outcome occurred in 116 of 404 patients in the CRT group, as compared with 102 of 405 in the control group (28.7% vs. 25.2%; hazard ratio, 1.20; 95% confidence interval [CI], 0.92 to 1.57; P=0.15). There were 45 deaths in the CRT group and 26 in the control group (11.1% vs. 6.4%; hazard ratio, 1.81; 95% CI, 1.11 to 2.93; P=0.02). CONCLUSIONS In patients with systolic heart failure and a QRS duration of less than 130 msec, CRT does not reduce the rate of death or hospitalization for heart failure and may increase mortality.</EA>
<CC>002B01; 002B12A01</CC>
<FD>Insuffisance cardiaque; Traitement instrumental; Médecine; Resynchronisation cardiaque</FD>
<FG>Stimulation instrumentale; Pathologie de l'appareil circulatoire; Cardiopathie</FG>
<ED>Heart failure; Instrumentation therapy; Medicine; Cardiac resynchronization</ED>
<EG>Instrumental stimulation; Cardiovascular disease; Heart disease</EG>
<SD>Insuficiencia cardíaca; Tratamiento instrumental; Medicina</SD>
<LO>INIST-6013.354000505862220050</LO>
<ID>13-0314576</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000795 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000795 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0314576
   |texte=   Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex

Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri